Tiziana Life Sciences Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Tiziana Life Sciences Ltd (TLSA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Tiziana Life Sciences Ltd vs Its Competitors
- Scale: Tiziana Life Sciences Ltd ranks #289 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Tiziana Life Sciences Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Tiziana Life Sciences Ltd | - | - | - | Yes |
| Competitors combined (127) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
TLSA Stock Performance relative to its Competitors
TLSA Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 5 | Dianthus Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Tiziana Life Sciences Ltd's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Tiziana Life Sciences Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Tiziana Life Sciences Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Tiziana Life Sciences Ltd | - | - |
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Beone Medicines Ltd | 552,467.82 | 6,128.24 |
| Abbvie Inc | 471,581.88 | 64,386.00 |
| Merck and Co Inc | 367,264.30 | 66,569.00 |
| SUBTOTAL | 5,042,189.02 | 826,405.95 |
Sign in to see all competitors of Tiziana Life Sciences Ltd.
Sources: Tiziana Life Sciences Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Tiziana Life Sciences Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Tiziana Life Sciences Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Sorafenib | Named by the company | 85% |
| Foralumab | Named by the company | 85% |
| Lenvatinib | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Tiziana Life Sciences Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Tiziana Life Sciences Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Tiziana Life Sciences Ltd | - | - | -1,151,938 |
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Beone Medicines Ltd | 552,468 | 510,686 | 54,642 |
| Abbvie Inc | 471,582 | 1,129,579 | 110,807 |
| Merck and Co Inc | 367,264 | 887,587 | 42,267 |
| PEERS TOTAL | 5,042,189 | 1,013,886 | 150,669 |
Sign in to see all peers for Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Tiziana Life Sciences Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Tiziana Life Sciences Ltd ranks #289 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 823, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,058,838 | 19.26 % |
| 2 | Johnson and Johnson | 663,585 | 12.07 % |
| 3 | Beone Medicines Ltd | 552,468 | 10.05 % |
| 4 | Abbvie Inc | 471,582 | 8.58 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 289 | Tiziana Life Sciences Ltd | 102 | 0.00 % |
Market cap and industry share for the rest of Tiziana Life Sciences Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Tiziana Life Sciences Ltd's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 284 | Aardvark Therapeutics Inc | 115 | -58.96 % |
| 285 | Genelux Corporation | 111 | -41.81 % |
| 286 | Nrx Pharmaceuticals Inc | 108 | 0.69 % |
| 287 | Rafael Holdings Inc | 103 | 42.28 % |
| 288 | Medicinova Inc | 1,234 | 12.3% |
| 289 | Tiziana Life Sciences Ltd | 102 | -51.97 % |
| 290 | Milestone Pharmaceuticals Inc | 1,234 | 12.3% |
| 291 | Rallybio Corporation | 1,234 | 12.3% |
| 292 | Polaryx Therapeutics Inc | 1,234 | 12.3% |
| 293 | Verrica Pharmaceuticals Inc | 1,234 | 12.3% |
| 294 | Promis Neurosciences inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Tiziana Life Sciences Ltd's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Tiziana Life Sciences Ltd's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | -160.84 % | -200.64 % | -3,333.12 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Tiziana Life Sciences Ltd's BCG Growth-Share Matrix
Relative market share (vs Tiziana Life Sciences Ltd's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Tiziana Life Sciences Ltd falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Tiziana Life Sciences Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 823 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Tiziana Life Sciences Ltd's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Tiziana Life Sciences Ltd's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Tiziana Life Sciences Ltd's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Tiziana Life Sciences Ltd falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Tiziana Life Sciences Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 35,470.5 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (34.20 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Tiziana Life Sciences Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Tiziana Life Sciences Ltd | 0.36 | 0.76 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Sign in to see all peers for Tiziana Life Sciences Ltd.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Tiziana Life Sciences Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Tiziana Life Sciences Ltd | Q4 2025 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +9.0 % | -6.0 % |
Sign in to see all peers for Tiziana Life Sciences Ltd.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Tiziana Life Sciences Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Tiziana Life Sciences Ltd | Q4 2025 | - | +10.5 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Sign in to see all peers for Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Tiziana Life Sciences Ltd | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
Sign in to see all peers for Tiziana Life Sciences Ltd.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Tiziana Life Sciences Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Tiziana Life Sciences Ltd | - | - |
| Eli Lilly And Company | 39.77 | 13.29 |
| Johnson and Johnson | 31.48 | 6.78 |
| Beone Medicines Ltd | 834.09 | 90.15 |
| Abbvie Inc | 75.22 | 7.32 |
| Merck and Co Inc | 119.91 | 5.52 |
| PEERS AVERAGE | 41.06 | 6.10 |
Sign in to see all peers for Tiziana Life Sciences Ltd.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.